A long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Study Status

Open to Enrollment

Study Description

This study is open to patients from previous PCI-32765 studies who meet eligibility criteria.

The purpose of this study is to determine the long-term safety and efficacy of a fixed-dose, daily regimen of PCI-32765 in patients with B-cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

PCI-32765 is a type of drug called a "kinase inhibitor." Kinases are proteins inside cells that help cells live and grow. The specific kinase blocked by PCI-32765 is believed to help blood cancer cells grow. By inhibiting the activity of this specific kinase, it is possible that PCI-32765 may kill the cancer cells or stop them from growing.

Sponsor

Pharmacyclics, Inc.

Key Eligibility

  • Men and women age 18 and older
  • B-Cell Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    • Stable disease or response to PCI-32765 for at least 6 months on a prior PCI-32765 study and want to continue study drug OR
    • Had disease progression on trial PCYC-04753 and want to try a higher dose
  • Detailed eligibility when you contact the study team

Principal Investigator

Richard Furman, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page